Abad M, Ciudad J, Rincon M R, Silva I, Paz-Bouza J I, Lopez A, Alonso A G, Bullon A, Orfao A
Department of Pathology, University Hospital, Salamanca, Spain.
Anal Cell Pathol. 1998;16(4):223-31. doi: 10.1155/1998/158243.
In the present study the prognostic value of both DNA ploidy and the proliferative activity of tumour cells were studied in a series of 76 consecutive patients suffering from gastric tumours. DNA ploidy and the proliferative index (as measured by the percentage of S-phase cells) were determined by flow cytometry using fresh tumour specimens. The presence of DNA aneuploid clones by flow cytometry was detected in 62% of the cases (mean DNA index of 1.63 +/- 0.46; range 1.08-2.92), the mean proportion of S-phase cells being of 18.4 +/- 11.5%. In comparison with diploid cases, aneuploid tumours showed a higher proliferative activity (cases with more than 15% S-phase cells: 18.4% versus 6.1%, p = 0.0001) as well as a higher incidence of node involvement (95% versus 68%, p = 0.001). By contrast, no significant differences were detected with respect to sex, age, histologic grade and type, clinical stage, tumour size and the incidence of extranodal involvement. Upon grouping the patients according to the proportion of S-phase cells no significant differences were observed for the clinical and biological parameters explored except for an association between a high percentage of S-phase cells and the presence of DNA aneuploidy (40% versus 96%, p = 0.0001). Regarding survival the presence of DNA aneuploidy was significantly associated with poor outcome as compared to the diploid cases (median of 15 versus 26 months, p = 0.005). By contrast, the proportion of S-phase cells did not predict patients's outcome. Multivariate analysis of prognostic factors showed that the presence of DNA aneuploidy (p = 0.003) together with the histologic type (p = 0.03) and the existence of extranodal metastases (p = 0.05) were the best combination of prognostic factors for survival prediction.
在本研究中,对76例连续的胃肿瘤患者进行了DNA倍体和肿瘤细胞增殖活性的预后价值研究。使用新鲜肿瘤标本通过流式细胞术测定DNA倍体和增殖指数(以S期细胞百分比衡量)。通过流式细胞术检测到62%的病例存在DNA非整倍体克隆(平均DNA指数为1.63±0.46;范围为1.08 - 2.92),S期细胞的平均比例为18.4±11.5%。与二倍体病例相比,非整倍体肿瘤显示出更高的增殖活性(S期细胞超过15%的病例:18.4%对6.1%,p = 0.0001)以及更高的淋巴结受累发生率(95%对68%,p = 0.001)。相比之下,在性别、年龄、组织学分级和类型、临床分期、肿瘤大小及结外受累发生率方面未检测到显著差异。根据S期细胞比例对患者进行分组时,除了S期细胞高百分比与DNA非整倍体的存在相关(40%对96%,p = 0.0001)外,在所探讨的临床和生物学参数方面未观察到显著差异。关于生存情况,与二倍体病例相比,DNA非整倍体的存在与不良预后显著相关(中位数为15个月对26个月,p = 0.005)。相比之下,S期细胞比例不能预测患者的预后。预后因素的多变量分析表明,DNA非整倍体的存在(p = 0.003)、组织学类型(p = 0.03)和结外转移的存在(p = 0.05)是生存预测的最佳预后因素组合。